Gregory A Otterson, MD

College

College of Medicine

Department/Division

Internal Medicine

Academic Title

Professor

Research Program

Translational Therapeutics

Research Interest

Cancer, Lung Cancer, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Retinoblastoma, Fatigue, Mesothelioma, Fanconi Anemia

Gregory Otterson, MD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on thoracic malignancies.

In particular, he is interested in genetic and epigenetic changes in lung cancers. He also seeks to understand which patients will best respond to specific therapeutic maneuvers.

One of his recent studies revealed that patients with fewer than four brain metastases from non-small cell lung cancer or breast cancer, and who had only stereotactic radiosurgery, survived longer than patients who had whole-brain radiation therapy.

Dr. Otterson has co-authored many articles that have appeared in such well-respected journals as Clinical Lung Cancer, Cancer, Molecular Cancer and Journal of Clinical Oncology.

Office Location

B450 Starling Loving Hall

320 W 10th Ave, Columbus, OH 43210

614-293-9424

614-293-4372

otterson.1@osu.edu;GREG.OTTERSON@OSUMC.EDU

Publications

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.

Yang SC, Gregory K, Aisner DL, Lin J, Chang JY, Loo BW Jr, Lanuti M, Stevenson J, Otterson GA, Tauer K, Govindan R, Hughes M, Gubens MA, Bauman J, Shapiro TA, Ettinger DS, Dobelbower M, Akerley W, Chirieac LR, Martins R, Swanson SJ, Patel SP, Dilling TJ, Lilenbaum R, Riely GJ, Lackner RP, D'Amico TA, Wood DE, Reckamp K, Leal TA, Hennon M, Horn L, Schild SE

J Natl Compr Canc Netw 16 807-821 07/01/2018
Expression patterns, prognostic value, and intratumoral heterogeneity of PD-L1 and PD-1 in thymoma and thymic carcinoma.

Chu B, Owen D, Lehman AM, Otterson GA, Shilo K, Annamalai L, Yearley JH

J Thorac Oncol in press 04/24/2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Reck M, Green G, Pluzanski A, Minenza E, Chang H, Otterson GA, Bhagavatheeswaran P, Paz-Ares L, Szustakowski J, Borghaei H, Burgers S, Salman P, Linardou H, Ramalingam SS, Hellmann MD, Fu Y, Healey D, Nathan F, O'Byrne KJ, Audigier-Valette C, Brahmer J, Geese WJ, Ciuleanu TE, Lee JS

N Engl J Med in press 04/16/2018
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.

Grecula J, Allan E, Otterson GA, Haglund KE, DiCostanzo D, Xu-Welliver M, Ayan A, Williams T, Bazan JG, Scoville N, Barney CL

Int J Radiat Oncol Biol Phys 100 748-755 03/01/2018
The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer.

Otterson GA, Xu-Welliver M, Bertino EM, Williams TM, He K, Shields PG, Carbone DP, Miller ED, Fisher JL, Grecula JC, Haglund KE, Bazan JG

J Thorac Oncol in press 12/18/2017
The Impact of Smoking and TP53 mutations in lung adenocarcinoma patients with targetable mutations - the Lung Cancer Mutation Consortium (LCMC2).

Ramalingam S, Waqar S, Minna JD, Sholl LM, Kugler K, Moreira AL, Otterson GA, Haura EB, Aisner DL, Politi K, Shyr Y, Sequist LV, Villaruz LC, Garon E, Rossi M, Johnson BE, Kris MG, Berry L, Glisson BS, Kwiatkowski DJ, Schiller J, Chen H, Wistuba II, Brahmer JR, Bunn PA, Fujimoto J, Cetnar J

Clin Cancer Res in press 12/07/2017
Epigenetic Therapeutics and Their Impact in Immunotherapy of Lung Cancer.

He K, Herman JG, Oezkan F, Otterson GA, Cho JH, Koenig M

Curr Pharmacol Rep 3 360-373 12/01/2017
Comprehensive Next-Generation Sequencing Analysis is Recommended for the Management of Patients With Melanoma.

Otterson G, Shilo K, Yao K, Bajestani S, Gru A, Zhao W

Appl Immunohistochem Mol Morphol in press 11/22/2017
Lung Cancer Patients with Germline Mutations detected by next generation sequencing and/or liquid biopsy.

Shukuya T, Patel S, Shane-Carson K, He K, Bertino EM, Shilo K, Otterson GA, Carbone DP

J Thorac Oncol in press 10/05/2017
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S

Oncotarget 8 75822-75833 09/29/2017
Malignant Melanoma Presenting as Thoracic Midline Malignancy: Clinicopathologic and Molecular Features.

Yao K, Zhao W, Bajestani S, Gru A, Otterson G, Shilo K

Appl Immunohistochem Mol Morphol in press 08/02/2017
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, Doebele RC, Govindan R, Gubens MA, Hennon M, Horn L, Komaki R, Lackner RP, Lanuti M, Leal TA, Leisch LJ, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M

J Natl Compr Canc Netw 15 504-535 04/01/2017
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F, Ignatius Ou SH, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F

J Thorac Oncol 12 145-151 01/01/2017
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.

Ou SI, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F, Ignatius Ou SH, Govindan R, Eaton KD, Otterson GA, Gutierrez ME, Mita AC, Argiris A, Brega NM, Usari T, Tan W, Ho SN, Robert F

J Thorac Oncol 12 145-151 01/01/2017
Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Thomas Purcell W, Ross Camidge D, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M

Nat Commun 7 13513 11/14/2016
Treatment of Lung Cancer Patients With Actionable Mutations in the Intensive Care Unit.

Kerrigan K, Shoben A, Otterson G

Clin Lung Cancer 17 523-527 11/01/2016
Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm.

Chu BF, Otterson GA

Clin Lung Cancer 17 493-506 11/01/2016
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies.

Shukuya T, Mori K, Amann JM, Bertino EM, Otterson GA, Shields PG, Morita S, Carbone DP

J Thorac Oncol 11 1927-1939 11/01/2016
A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.

Chiappori AA, Otterson GA, Dowlati A, Traynor AM, Horn L, Owonikoko TK, Ross HJ, Hann CL, Abu Hejleh T, Nieva J, Zhao X, Schell M, Sullivan DM

Oncologist 21 1163-1164 10/01/2016
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.

Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson Md GA, Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson GA

Mol Cancer Ther 15 2244-50 09/01/2016
A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer.

Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson Md GA, Bertino EM, McMichael EL, Mo X, Trikha P, Davis M, Paul B, Grever M, Carson WE, Otterson GA

Mol Cancer Ther 15 2244-50 09/01/2016
Lung cancer exosomes as drivers of epithelial mesenchymal transition.

Rahman MA, Barger JF, Lovat F, Gao M, Otterson GA, Nana-Sinkam P

Oncotarget 7 54852-54866 08/23/2016
Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.

Halasz LM, Uno H, Hughes M, D'Amico T, Dexter EU, Edge SB, Hayman JA, Niland JC, Otterson GA, Pisters KM, Theriault R, Weeks JC, Punglia RS

Cancer 122 2091-100 07/01/2016
NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M

J Natl Compr Canc Netw 14 825-36 07/01/2016
Rad51C-ATXN7 fusion gene expression in colorectal tumors.

Kalvala A, Gao L, Aguila B, Dotts K, Rahman M, Nana-Sinkam SP, Zhou X, Wang QE, Amann J, Otterson GA, Villalona-Calero MA, Duan W

Mol Cancer 15 47 06/13/2016
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.

Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, Kurtz DM, Stehr H, Scherer F, Karlovich CA, Harding TC, Durkin KA, Otterson GA, Purcell WT, Camidge DR, Goldman JW, Sequist LV, Piotrowska Z, Wakelee HA, Neal JW, Alizadeh AA, Diehn M

Nat Commun 7 11815 06/10/2016
Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.

Villalona-Calero MA, Lam E, Otterson GA, Zhao W, Timmons M, Subramaniam D, Hade EM, Gill GM, Coffey M, Selvaggi G, Bertino E, Chao B, Knopp MV

Cancer 122 875-83 03/15/2016
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M

J Natl Compr Canc Netw 14 255-64 03/01/2016
Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients.

Bertino EM, Williams TM, Nana-Sinkam SP, Shilo K, Chatterjee M, Mo X, Rahmani M, Phillips GS, Villalona-Calero MA, Otterson GA

Clin Lung Cancer 16 466-74 11/01/2015
CT Gray-Level Texture Analysis as a Quantitative Imaging Biomarker of Epidermal Growth Factor Receptor Mutation Status in Adenocarcinoma of the Lung.

Ozkan E, West A, Dedelow JA, Chu BF, Zhao W, Yildiz VO, Otterson GA, Shilo K, Ghosh S, King M, White RD, Erdal BS

AJR Am J Roentgenol 205 1016-25 11/01/2015
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.

Halmos B, Pennell NA, Fu P, Saad S, Gadgeel S, Otterson GA, Mekhail T, Snell M, Kuebler JP, Sharma N, Dowlati A

Oncologist 20 1298-303 11/01/2015
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).

Ready NE, Pang HH, Gu L, Otterson GA, Thomas SP, Miller AA, Baggstrom M, Masters GA, Graziano SL, Crawford J, Bogart J, Vokes EE

J Clin Oncol 33 1660-5 05/20/2015
Non-Small Cell Lung Cancer, Version 6.2015.

Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW Jr, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M

J Natl Compr Canc Netw 13 515-24 05/01/2015
Overexpression of Rad51C splice variants in colorectal tumors.

Kalvala A, Gao L, Aguila B, Reese T, Otterson GA, Villalona-Calero MA, Duan W

Oncotarget 6 8777-87 04/20/2015
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS

Lancet Oncol 16 257-65 03/01/2015
Mutational profiling of second primary lung cancers in patients who have received radiation for the treatment of Hodgkin's disease.

Bond DA, Dunavin N, Otterson GA

Cancer Invest 33 86-8 03/01/2015
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer.

Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL

J Clin Oncol 33 189-94 01/10/2015
Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines.

Wood DE, Kazerooni E, Baum SL, Dransfield MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar R, Lackner RP, Leard LE, Leung AN, Makani SS, Massion PP, Meyers BF, Otterson GA, Peairs K, Pipavath S, Pratt-Pozo C, Reddy C, Reid ME, Rotter AJ, Sachs PB, Schabath MB, Sequist LV, Tong BC, Travis WD, Yang SC, Gregory KM, Hughes M

J Natl Compr Canc Netw 13 23-34; quiz 34 01/01/2015
Metastatic Squamous Cell Carcinoma Component from an Adenosquamous Carcinoma of the Lung with Identical Epidermal Growth Factor Receptor Mutations.

Burkart J, Shilo K, Zhao W, Ozkan E, Ajam A, Otterson GA

Case Rep Pulmonol 2015 283875 01/01/2015
Clinical and metabolic parameters in non-small cell lung carcinoma and colorectal cancer patients with and without KRAS mutations.

Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou XP, Frankel W, Otterson GA, Zhao W

Int J Environ Res Public Health 11 8645-60 09/01/2014
Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations.

Yilmaz A, Mohamed N, Patterson KA, Tang Y, Shilo K, Villalona-Calero MA, Davis ME, Zhou X, Frankel W, Otterson GA, Beall HD, Zhao W

Int J Environ Res Public Health 11 9491-502 09/01/2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analyses.

Phelps MA, Stinchcombe TE, Blachly JS, Zhao W, Schaaf LJ, Starrett SL, Wei L, Poi M, Wang D, Papp A, Aimiuwu J, Gao Y, Li J, Otterson GA, Hicks WJ, Socinski MA, Villalona-Calero MA

Clin Pharmacol Ther 96 182-91 08/01/2014
Y-chromosome status identification suggests a recipient origin of posttransplant non-small cell lung carcinomas: chromogenic in situ hybridization analysis.

Chen W, Brodsky SV, Zhao W, Otterson GA, Villalona-Calero M, Satoskar AA, Hasan A, Pelletier R, Ivanov I, Ross P, Nadasdy T, Shilo K

Hum Pathol 45 1065-70 05/01/2014
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Gitlitz BJ, Bernstein E, Santos ES, Otterson GA, Milne G, Syto M, Burrows F, Zaknoen S

J Thorac Oncol 9 577-82 04/01/2014
Molecular pathways and therapeutic targets in lung cancer.

Shtivelman E, Hensing T, Simon GR, Dennis PA, Otterson GA, Bueno R, Salgia R

Oncotarget 5 1392-433 03/30/2014
NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.

Eisfeld AK, Schwind S, Hoag KW, Walker CJ, Liyanarachchi S, Patel R, Huang X, Markowitz J, Duan W, Otterson GA, Carson WE 3rd, Marcucci G, Bloomfield CD, de la Chapelle A

Proc Natl Acad Sci U S A 111 4179-84 03/18/2014
CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer.

Heist RS, Wang X, Hodgson L, Otterson GA, Stinchcombe TE, Gandhi L, Villalona-Calero MA, Watson P, Vokes EE, Socinski MA, Alliance for Clinical Trials in Oncology

J Thorac Oncol 9 214-21 02/01/2014
Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC.

Ou SH, Jänne PA, Bartlett CH, Tang Y, Kim DW, Otterson GA, Crinò L, Selaru P, Cohen DP, Clark JW, Riely GJ

Ann Oncol 25 415-22 02/01/2014
Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer.

Duan W, Gao L, Aguila B, Kalvala A, Otterson GA, Villalona-Calero MA

Front Oncol 4 368 01/01/2014
Detection of extracellular RNAs in cancer and viral infection via tethered cationic lipoplex nanoparticles containing molecular beacons.

Wu Y, Kwak KJ, Agarwal K, Marras A, Wang C, Mao Y, Huang X, Ma J, Yu B, Lee R, Vachani A, Marcucci G, Byrd JC, Muthusamy N, Otterson G, Huang K, Castro CE, Paulaitis M, Nana-Sinkam SP, Lee LJ

Anal Chem 85 11265-74 12/03/2013